Management and Board
Management
Carolina Trkulja
VD
CEO since 2023.
Born 1984.
Carolina has a PhD in biophysical chemistry from Chalmers University of Technology in Gothenburg. Carolina Trkulja was hired as Chief Innovation Officer at Fluicell, where she led the company's research collaborations. She has broad experience in drug development, with particular expertise in lead generation and preclinical development. Carolina, who is the founder of ObliqueTherapeutics, has contributed to several patents and published her research results in renowned scientific journals. Her previous role as Chief Scientific Officer at Oblique Therapeutics AB has given her extensive experience in research and drug development.
Owns 8,644 shares in Fluicell (May 31, 2025).
Joakim Wahlberg
Chief Financial Officer
CFO since 2023.
Born 1970.
Joakim has a licentiate degree from the School of Economics at the University of Gothenburg and intends to defend his doctoral thesis in business administration at the same university during the winter of 2023/24. Joakim Wahlberg has over two decades of experience leading complex financial operations, including his previous role as CFO at Pulsen Group, where he led the transformative modernization of the finance function. In addition, Joakim is completing his doctorate in business administration at the Gothenburg School of Economics. His research focuses on financial management as a dynamic capability and its role in driving strategic development and fostering innovation within organizations.
Owns 13,020 shares in Fluicell personally and through JW Business Control (Mar 10, 2026).
Gavin D. M. Jeffries
CHIEF TECHNOLOGY OFFICER
CTO since 2017.
Born 1980.
Gavin is currently the CTO of Fluicell AB and holds a PhD in Chemistry from the University of Washington, Seattle. He was a research assistant at Chalmers University of Technology for 4 years and has published over forty peer-reviewed scientific publications, with a total number of citations of over a thousand. Gavin is an entrepreneur and founder of two biotechnology and optics companies, inventor of several patents and technologies, and has a strong background in microfluidics, single-cell analysis and optical platform integration.
Owns 6,615 shares in Fluicell (May 31, 2025).
Jonas Hannestad
CHIEF MARKETING & COMMUNICATIONS OFFICER
Chief Marketing & Communication Officer since 2020.
Born 1981.
Jonas has a PhD in physical chemistry from Chalmers Institute of Technology, Gothenburg and research experience as a postdoctoral fellow at RISE Research Institutes of Sweden and Chalmers Institute of Technology. Jonas combines his research background with experience from project management in research communication in the borderland between science and art with a focus on the intersection between science, technology and society.
Jonas Hannestad owns 3,138 shares in Fluicell (May 31, 2025).
Board
Niklas Frisk
Chairman of the board since 2026.
Born 1975.
Niklas Frisk is an investor and entrepreneur with board assignments in VPUS Joyous Group and OhMungood AB, among others. Niklas has previously been Senior Vice President of Oriflame where he as a member of Group Management was first responsible for Asia and then Africa and Europe during the period 2012–2020. Prior to that, Niklas worked for 17 years at Alcro-Beckers AB, of which the final seven years as CEO when the company was also listed on Nasdaq Helsinki. He has also been Chairman of the Board of SVEFF – Sveriges Förenade Färgfabrikanter, Chairman of the Board of the Färgglädje Group and also Chairman of the Board of IDSA India. Niklas holds an economics degree and an MBA from the Stockholm School of Economics and the University of Virginia.
Independent in relation to the company and major shareholders.
Owns 41,290 shares in Fluicell (May 31, 2026).
Owe Orwar
Board member since 2015.
Born 1964.
Owe is Senior Group Leader at Karolinska Institutet. After completing a PhD in chemistry from the University of Gothenburg, he completed two years of postdoctoral studies at Stanford University. Owe has previous experience as Global VP of R&D at Sanofi, President of R&D at Piramal Healthcare, as well as entrepreneur, inventor and founder of six biotechnology companies. Owe has a total of over 20 years of experience in the pharmaceutical and biotechnology industry, holds more than 75 patents, is the author of hundreds of research articles and is a pioneer in the research areas of single-cell biology and biophysics with several products on the global market.
Dependent in relation to the company / Independent in relation to major shareholders.
Owns 7,602 shares in Fluicell through Clavis & Vose Invest AB (May 31, 2026).
Karin Jennbacken
Board member since 2026.
Born in 1977.
Karin is Executive Director and Head of Cardiovascular Bioscience within BioPharmaceuticals R&D at AstraZeneca, where she leads strategic and scientific work in cardiovascular research and early drug development. She is a trained pharmacist and has a PhD in oncology from the University of Gothenburg. Karin has a strong scientific background in cardiovascular research, regenerative medicine and advanced cell models, as well as long and broad experience from the pharmaceutical industry. She has held leading roles throughout the drug development chain and is the author of several scientific publications.
Independent in relation to the company and major shareholders.
Currently doesn't own shares in Fluicell.
Daniel T. Chiu
Board member since 2017.
Born 1972.
Graduated from Harvard, Stanford and UC Berkeley.Daniel has been a professor of chemistry and biotechnology at the University of Washington since 2006. After graduating from Stanford University, he completed postdoctoral research at Harvard University. Scientific founder of several life science and biotech companies in Asia, Europe and the USA. Member and Chair of numerous government and industry advisory and review panels. He is a pioneer in the field of single-cell biology with several products on the global market. Daniel has authored more than 200 scientific publications and is an inventor on over 60 issued patents.
Independence in relation to the company and major shareholders.
Daniel owns no shares in Fluicell
Carl Fhager
Board member since 2017.
Born 1975.
Law degree, Gothenburg University.Carl is an experienced and recognized lawyer at MAQS Gothenburg office. He has extensive experience in commercial agreements, including cooperation, commissions and purchases as well as contractual terms. He specializes in the sports, media and entertainment industry, where he has worked for over ten years, in addition to being the sports director for the football club BK Häcken for four years. Thanks to Carl's dual legal and management background, he has helped many boards in an advisory role, or as a member or chairman.
Independence in relation to the company and major shareholders.
Does not own shares in Fluicell (December 31, 2024).
Alex Scheepers
Board member since 2026.
Born in 1974.
Alex Scheepers is a senior executive with more than 20 years of experience in the pharmaceutical and advanced manufacturing sectors, including over a decade leading large, highly regulated organisations within Recipharm and Octapharma. He brings deep expertise in strategic leadership, financial oversight, operational transformation and governance in complex global environments. Alex has a strong track record of improving performance and executing major transformation programs, while aligning organisations behind clear long-term strategies. With an MBA from the Stockholm School of Economics and executive training from INSEAD, he combines analytical rigour with a pragmatic approach to value creation, with a particular interest in emerging technology and life science innovation.
Independent in relation to the company and major shareholders.
Currently doesn't own shares in Fluicell.
Peter Kjäll
Board member since 2026.
Born in 1978.
Peter Kjäll holds a Ph.D. in Medical Sciences and working at the intersection of digital health, healthtech, and healthcare transformation. His expertise spans medtech, biotech, AI, welfare technology and eHealth, with a strong focus on commercialization, value creation, and implementation. With experience in risk assessment from a venture capital perspective and international matchmaking across academia, industry, and healthcare, he is actively working with enterprise politics and policymaking to create the best conditions for the industry to accelerate the adoption of technological innovations that shape the future of healthcare.
Independent in relation to the company and major shareholders.
Currently doesn't own shares in Fluicell.
Kader Abdul
Board member since 2026.
Born in 1976.
Kader Abdul holds a Master's degree in Microbiology from the University of Dhaka, an MBA in Marketing from the Institute of Business Administration and a PhD from the Department of Microbiology, Tumor and Cell Biology (MTC) at Karolinska Institutet. Kader has been part of several research groups, including at the Wenner-Gren Center, the Swedish Medical Nanoscience Center and Karolinska Institutet. Kader has been involved in several small and medium-sized companies where he has helped them position themselves in the global market. He has also worked in various roles at several organizations globally and has been particularly interested in the positive impact of products and services. Kader Abdul is co-founder of Viola Vitalis AB and has been the company's CEO since 2010.
Independent in relation to the company and major shareholders.
Owns 61,605 shares in Fluicell (May 31, 2026).